Tech Company Financing Transactions
Repertoire Immune Medicines Funding Round
Alaska Permanent Fund, Invus and PSP Investments invested in a $189 million Series B funding round for Repertoire Immune Medicines. The financing was announced on 4/14/2021.
Transaction Overview
Company Name
Announced On
4/14/2021
Transaction Type
Venture Equity
Amount
$189,000,000
Round
Series B
Proceeds Purpose
Proceeds from this financing will support further expansion of the company's proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire's team, and enhance its manufacturing capabilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Repertoire Immune Medicines is founded on the belief that the repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Cox
Chief Financial Officer
Sok Soh
Chief Scientific Officer
Jan Kisielow
VP - Administration
Andrea Difabio
VP - Bus. Development
Timothy Harris
VP - Human Resources
Lucia Celona
VP - R & D
Anthony Coyle
Browse more venture capital transactions:
Prev: 4/14/2021: Clearcover venture capital transaction
Next: 4/14/2021: SambaNova Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs